Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Shares Are Falling Today

By Keith Speights - Jan 28, 2020 at 11:32AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors appear to be taking profits after coronavirus worries caused the biotech stock to soar yesterday and last week.

What happened

Shares of Novavax (NVAX 11.12%) were falling 12.7% lower as of 10:54 a.m. on Tuesday. There wasn't any real news driving Novavax's decline. Instead, investors appear to be taking profits off the table after the stock's big gains stemming from concerns about the spread of a deadly coronavirus strain.

So what

When a stock moves a lot higher in a short period of time on news that doesn't definitively translate to improved prospects, it's likely to be very volatile. That's the story in a nutshell for Novavax's big price swings.

Concerns about the coronavirus that first infected residents of Wuhan, China, are warranted. The virus has spread to the U.S. and other countries. It presents a serious health threat.

Masked healthcare professional holding a syringe and vaccine bottle

Image source: Getty Images.

Investors' interest in Novavax and other biotech stocks that have development programs that could target the coronavirus strain is also warranted. If the virus continues to spread, the first company to develop a safe and effective vaccine or antiviral drug for the virus could make a fortune.

However, there are some major assumptions that might not pan out. Novavax might be successful with its coronavirus program, but it might not. The virus might continue to spread, but it might not. Today's sell-off of Novavax shares reflects this uncertainty.

Now what

It makes sense for investors to closely watch the progress of biotechs like Novavax with their efforts to develop drugs and vaccines targeting the coronavirus. However, it's even more important to be on the lookout for other key milestones. The biggest upcoming catalyst for Novavax is its anticipated results from a late-stage study of nanoparticle-based flu vaccine NanoFlu that should be announced within the next couple of months.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$57.15 (11.12%) $5.72

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.